Piper Sandler has increased its price target for Inspire Medical Systems to $70 from $60, while maintaining a Neutral rating. This adjustment suggests a modest potential upside of 4.2% from the previous closing price, indicating a slightly more optimistic but still cautious outlook from the analyst.
Piper Sandler has updated its price target for Inspire Medical Systems (INSP) from $60 to $70, representing a 16.7% increase. Despite this, the firm maintained a Neutral rating, suggesting that while the valuation has improved, they don't see a compelling reason for significant outperformance. The new target implies a modest 4.2% upside from the November 2, 2026 closing price of $67.21. This news primarily affects INSP shareholders and potential investors, offering a slightly more positive, but still tempered, view on the stock's near-term potential. For traders, this indicates a minor positive sentiment shift, but the Neutral rating suggests limited catalyst for a major price movement in either direction in the short term. The long-term implications are tied to whether the company can exceed these revised expectations.